ALVAL Stock Overview
Engages in the research and development of health nutrition products to prevent and control metabolic and cardiovascular diseases in France.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Valbiotis SA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €1.29 |
52 Week High | €7.50 |
52 Week Low | €1.15 |
Beta | -0.36 |
1 Month Change | -70.38% |
3 Month Change | -66.67% |
1 Year Change | -70.62% |
3 Year Change | -81.96% |
5 Year Change | -65.14% |
Change since IPO | -87.10% |
Recent News & Updates
Shareholder Returns
ALVAL | FR Biotechs | FR Market | |
---|---|---|---|
7D | -35.5% | -7.4% | -4.2% |
1Y | -70.6% | -23.2% | 1.8% |
Return vs Industry: ALVAL underperformed the French Biotechs industry which returned -23.2% over the past year.
Return vs Market: ALVAL underperformed the French Market which returned 1.8% over the past year.
Price Volatility
ALVAL volatility | |
---|---|
ALVAL Average Weekly Movement | 14.6% |
Biotechs Industry Average Movement | 6.6% |
Market Average Movement | 4.5% |
10% most volatile stocks in FR Market | 9.3% |
10% least volatile stocks in FR Market | 2.4% |
Stable Share Price: ALVAL's share price has been volatile over the past 3 months.
Volatility Over Time: ALVAL's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | 52 | Sebastien Peltier | www.valbiotis.com |
Valbiotis SA engages in the research and development of health nutrition products to prevent and control metabolic and cardiovascular diseases in France. The company develops TOTUM-63 for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II/III clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with MASLD.
Valbiotis SA Fundamentals Summary
ALVAL fundamental statistics | |
---|---|
Market cap | €20.36m |
Earnings (TTM) | -€7.37m |
Revenue (TTM) | €4.73m |
4.3x
P/S Ratio-2.8x
P/E RatioIs ALVAL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ALVAL income statement (TTM) | |
---|---|
Revenue | €4.73m |
Cost of Revenue | €2.04m |
Gross Profit | €2.69m |
Other Expenses | €10.06m |
Earnings | -€7.37m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Oct 29, 2024
Earnings per share (EPS) | -0.47 |
Gross Margin | 56.81% |
Net Profit Margin | -155.67% |
Debt/Equity Ratio | 28.1% |
How did ALVAL perform over the long term?
See historical performance and comparison